

# PIPELINE REPORT

## Generic Drugs

July 2019



BRAND NAME	GENERIC NAME	MANUFACTURER	ESTIMATED LAUNCH DATE*	THERAPEUTIC USE	POTENTIAL IMPACT
Abelcet	amphotericin B lipid complex	Sigma Tau	June 2019	Fungal Infections	Low
Absorica	isotretinoin	Ranbaxy	4Q 2020	Acne	High
Afinitor (2.5mg, 5mg, 7.5mg)	everolimus	Novartis	4Q 2019	Cancer	High
Afinitor 10mg	everolimus	Novartis	2019-2022	Cancer	High
Antara (30, 90 mg)	fenofibrate micronized capsules	Reliant	2020-2022	High Blood Cholesterol	Moderate
Apriso	mesalamine	Salix	2019	Inflammatory Conditions	Moderate
Aptensio XR	methylphenidate	Rhodes	2019	Attention Disorders	Low
Aptivus	tipranavir	Boehringer Ingelheim	2Q 2020	HIV	Low
Azasite	azithromycin drops	Inspire	2Q 2019	Eye Infections	Moderate
BiDil	hydralazine / isosorbide dinitrate	Arbor	Sept 2020	High Blood Pressure/ Heart Disease	Low
Byetta	exenatide inj	AstraZeneca	2019 / 2020	Diabetes	Low
Chantix	varenicline	Pfizer	2020-2022	Smoking Cessation	High
CiproDex Otic	ciprofloxacin/ dexamethasone ophth	Alcon	2020	Eye Infections	High
Cystaran	cysteamine hcl	Sigma Tau	Oct 2019	Ophthalmic Conditions	Low
Daliresp	roflumilast	Forest	2020-2021	COPD	Moderate
Desonate	desonide	Leo Pharm	2019	Misc Conditions	Moderate
Dexilant	dexlansoprazole	Takeda	2020-2023	Heartburn/Ulcer Disease	High
Doryx MPC	doxycycline hyclate	Mayne	2020	Infections	Moderate
Dulera	formoterol / mometasone	Merck	May 2020	Asthma	High
Durezol	difluprednate	Sirion	2019	Ophthalmic Conditions	Moderate
Emend Inj.	fosaprepitant dimeglumine	Merck	Sept 2019	Nausea/Vomiting	Low
Endometrin	progesterone	Ferring	Nov 2019	Vaginal Disorders	Moderate
Entereg	alvimopan	Cubist	Nov 2020	Constipation	Low
Epiduo Forte	adapalene/benzoyl peroxide	Astellas	2020-2021	Acne	High

# PIPELINE REPORT

## Generic Drugs

July 2019



BRAND NAME	GENERIC NAME	MANUFACTURER	ESTIMATED LAUNCH DATE*	THERAPEUTIC USE	POTENTIAL IMPACT
Ferriprox	deferiprone	ApoPharma	2019-2020	Iron Toxicity	Low
Firazyr	icatibant acetate	Shire	July 2019	Hereditary Angioedema	Moderate
Forteo	teriparatide	Lilly	2H 2019	Osteoporosis	High
Gelnique	oxybutynin	Watson	2020-2026	Urinary Disorders	Moderate
Jadenu	deferasirox	Novartis	Oct 2019	Iron Toxicity	Moderate
Kaletra Capsules	lopinavir / ritonavir	AbbVie	Nov 2020	HIV	High
Kaletra Tablets	lopinavir	AbbVie	2019-2020	HIV	High
Kuvan	sapropterin hydrochloride	Biomarin	Oct 2020	Endocrine Disorders	Low
Lyrica	pregabalin	Pfizer	June 2019	Pain and Inflammation	High
Lyrica Oral Solution	pregabalin	Pfizer	June 2019	Pain and Inflammation	High
Moviprep	polyethylene glycol 3350	Salix	1H 2019	Constipation	Low
Moxeza	moxifloxacin	Alcon	2019	Infections	High
Mycamine	miconazole	Astellas	2020	Fungal Infections	Low
Mydayis	mixed amphetamines	Shire	June 2020	Attention Disorders	Moderate
Norvir capsules	ritonavir	AbbVie	2019-2020	HIV	Moderate
Noxafil Suspension	posaconazole	Merck	Jan 2020	Fungal Infections	High
Noxafil tablets	posaconazole	Schering-Plough	Jan 2020	Fungal Infections	High
Nuvaring	E.E./etonogestrel	Organon	2019	Contraceptives	High
Ofirmev	acetaminophen	Cadence	4Q 2020	Pain and Inflammation	Low
Omnaris	ciclesonide	Sunovion	2019-2020	Allergies	Low
Pomalyst	pomalidomide	Celgene	3Q 2020	Cancer	High
Prepopik	citric acid / magnesium oxide / sodium picosulfate	Ferring	2019	Constipation	Moderate
Prestalia	amlodipine / perindopril	Symplmed	2019	High Blood Pressure/ Heart Disease	Low
Pylera	bismacitrate, metronidazole, TCN	Axcan	2019	GI	Low

# PIPELINE REPORT

## Generic Drugs

July 2019



BRAND NAME	GENERIC NAME	MANUFACTURER	ESTIMATED LAUNCH DATE*	THERAPEUTIC USE	POTENTIAL IMPACT
Relistor tablets	methylnaltrexone bromide	Salix	July 2019	Constipation	Moderate
Renova	tretinoin	Johnson & Johnson	Mar 2020	Acne	Moderate
Rescriptor 200mg	delavirdine	Pfizer	June 2019	HIV	Low
Rescula	unoprostone isopropyl	Sucampo	2019-2021	Glaucoma	Low
Restasis	cyclosporin ophthalmic	Allergan	2019	Ophthalmic Conditions	High
Risperdal Consta	risperidone injection	Johnson & Johnson	Nov 2020	Mental/Neuro Disorders	Moderate
Rozerem	ramelteon	Takeda	2019	Sleep Disorders	Moderate
Samsca	tolvaptan	Otsuka	2019	Endocrine Disorders	Moderate
Saphris	asenapine	Organogenesis Inc.	1H 2020	Mental/Neuro Disorders	Moderate
Silenor	doxepin	Somaxon	Jan 2020	Sleep Disorders	Moderate
Sklice	ivermectin	Abor	May 2020	Skin Infections	Low
Striant	testosterone e.r. buccal tablet	Acient	Aug 2019	Hormonal Supplementation	Low
Syndros	dronabinol	Insys	2019-2020	HIV	Low
Synribo	omacetaxine	IVAX	Oct 2019	Cancer	Low
Taclonex Suspension	betamethasone dipropionate / calcipotriene	Leo Pharm	Jan 2020	Skin Conditions	Moderate
Taytulla	EE / norethindrone acetate	Allergan	Mar 2020	Contraceptives	High
Tecfidera	dimethyl fumarate	Biogen Idec	Sept 2020	Multiple Sclerosis	High
Thalomid	thalidomide	Celgene	2019-2020	Cancer	Moderate
Tirosint	levothyroxine	Akrimax	3Q 2020	Thyroid Disorder	High
Toviaz	fesoterodine	Pfizer	2020-2021	Urinary Disorders	Moderate
Tracleer (dispersible tablet for oral suspension)	bosentan	Actelion	2019-2020	Pulmonary Hypertension	Moderate
Travatan Z	travoprost	Alcon	2019	Glaucoma	Moderate
Tykerb	lapatinib	GlaxoSmithKline	Sept 2020	Cancer	Moderate

# PIPELINE REPORT

## Generic Drugs

July 2019



BRAND NAME	GENERIC NAME	MANUFACTURER	ESTIMATED LAUNCH DATE*	THERAPEUTIC USE	POTENTIAL IMPACT
Ulesfia	benzyl alcohol topical lotion	Shionogi	2019-2021	Skin Infections	Low
Vaprisol	conivaptan	Astellas	June 2020	Endocrine Disorders	Low
Velcade	bortezomib	Millenium	2020-2022	Cancer	Moderate
Veletri	epoprostenol sodium	Actelion	Nov 2019	Pulmonary Hypertension	Low
Velphoro	sucroferric	Fresenius	3Q 2020	Kidney Disease	Low
Viibryd	vilazodone	Forest	2020-2021	Depression	High
Vivlodex	meloxicam	Zyla Life Sciences	2019	Pain and Inflammation	Moderate
Zohydro ER	hydrocodone ER	Zogenix	4Q 2019	Pain and Inflammation	Moderate
Zortress	everolimus	Novartis	Mar 2020	Cancer	Moderate

\*Estimated launch dates are subject to change at any time due to legal proceedings, exclusivity, timing of FDA approvals, additional patents, etc.

#### References:

- FDA Electronic Orange Book. Available at: <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>. Accessed June 7, 2017.
- Drugs@FDA. Available at: <http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm>. Accessed June 7, 2017.